IN2014DN09610A - - Google Patents

Info

Publication number
IN2014DN09610A
IN2014DN09610A IN9610DEN2014A IN2014DN09610A IN 2014DN09610 A IN2014DN09610 A IN 2014DN09610A IN 9610DEN2014 A IN9610DEN2014 A IN 9610DEN2014A IN 2014DN09610 A IN2014DN09610 A IN 2014DN09610A
Authority
IN
India
Prior art keywords
formula
ring
same
heteroatom
substituents
Prior art date
Application number
Inventor
Xiaodong Wang
Weihe Zhang
Dmitri Kireev
Dehui Zhang
Andrew Mciver
Original Assignee
Univ North Carolina
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ North Carolina filed Critical Univ North Carolina
Publication of IN2014DN09610A publication Critical patent/IN2014DN09610A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Described are compounds of Formula I or Formula II: wherein: ring A is a 5 - or 6- membered heteroaryl group; dashed lines are optional double bonds; X is N or O; Y is a carbon atom or an S or N heteroatom in ring A in any suitable location; and substituents are as given herein. Compositions containing the same and methods of using the same in treating cancers such as acute lymphoblastic leukemia are also described.
IN9610DEN2014 2012-05-22 2013-05-21 IN2014DN09610A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261650000P 2012-05-22 2012-05-22
PCT/US2013/042033 WO2013177168A1 (en) 2012-05-22 2013-05-21 Pyrimidine compounds for the treatment of cancer

Publications (1)

Publication Number Publication Date
IN2014DN09610A true IN2014DN09610A (en) 2015-07-31

Family

ID=49624289

Family Applications (1)

Application Number Title Priority Date Filing Date
IN9610DEN2014 IN2014DN09610A (en) 2012-05-22 2013-05-21

Country Status (14)

Country Link
US (1) US9567326B2 (en)
EP (1) EP2852579A4 (en)
JP (1) JP2015517574A (en)
KR (1) KR20150018789A (en)
CN (1) CN104302627A (en)
AU (1) AU2013266438B2 (en)
BR (1) BR112014028424A2 (en)
CA (1) CA2873878A1 (en)
HK (1) HK1206338A1 (en)
IL (1) IL235726A0 (en)
IN (1) IN2014DN09610A (en)
MX (1) MX2014013632A (en)
RU (1) RU2014145121A (en)
WO (1) WO2013177168A1 (en)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9290499B2 (en) 2010-05-19 2016-03-22 The University Of North Carolina At Chapel Hill Pyrazolopyrimidine compounds for the treatment of cancer
WO2013052417A1 (en) 2011-10-03 2013-04-11 The University Of North Carolina At Chapel Hill Pyrrolopyrimidine compounds for the treatment of cancer
RU2014145121A (en) 2012-05-22 2016-07-10 Зэ Юниверсити Оф Норд Каролина Эт Чапел Хилл PYRIMIDINE COMPOUNDS FOR TREATING A MALIGNANT TUMOR
EP2903617B1 (en) * 2012-10-08 2019-01-30 Merck Sharp & Dohme Corp. Inhibitors of irak4 activity
EP2909211A4 (en) 2012-10-17 2016-06-22 Univ North Carolina PYRAZOLOPYRIMIDINE COMPOUNDS FOR THE TREATMENT OF CANCER
EP2925752A4 (en) 2012-11-27 2016-06-01 Univ North Carolina PYRIMIDINE-BASED COMPOUNDS FOR USE IN THE TREATMENT OF CANCER
CN104926801B (en) 2014-03-22 2019-06-04 浙江大学 Substituted nitrogen heterocyclic derivatives, pharmaceutical compositions containing them and their application in antitumor
WO2015157122A1 (en) 2014-04-11 2015-10-15 The University Of North Carolina At Chapel Hill Mertk-specific pyrazolopyrimidine compounds
WO2017059280A1 (en) * 2015-10-02 2017-04-06 The University Of North Carolina At Chapel Hill Novel pan-tam inhibitors and mer/axl dual inhibitors
US10709708B2 (en) 2016-03-17 2020-07-14 The University Of North Carolina At Chapel Hill Method of treating cancer with a combination of MER tyrosine kinase inhibitor and an epidermal growth factor receptor (EGFR) inhibitor
WO2017197046A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. C3-carbon linked glutarimide degronimers for target protein degradation
CN109562113A (en) 2016-05-10 2019-04-02 C4医药公司 Spiro degron for target protein degradation
WO2017197051A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Amine-linked c3-glutarimide degronimers for target protein degradation
ES2989988T3 (en) 2016-05-10 2024-11-28 C4 Therapeutics Inc Heterocyclic degronimers for the degradation of target proteins
CA3028997A1 (en) 2016-06-27 2018-01-04 Rigel Pharmaceuticals, Inc. 2,4-diamino-pyrimidine compounds and method for making and using the compounds
CN106749173A (en) * 2016-11-25 2017-05-31 吉林化工学院 A kind of preparation method of pyrimidine bipyridyliumses compound
US11053225B2 (en) 2017-05-02 2021-07-06 Korea Research Institute Of Chemical Technology Pyrimidine derivative compound, optical isomer thereof, or pharmaceutically acceptable salt thereof, and composition for preventing or treating Tyro 3 related disease comprising same as active ingredient
CN110769822A (en) 2017-06-20 2020-02-07 C4医药公司 N/O-linked degron and degron bodies for protein degradation
EP3498694A1 (en) * 2017-12-12 2019-06-19 Medibiofarma, S.L. New benzamide derivatives as ppar-gamma modulators
CN120698983A (en) 2018-12-20 2025-09-26 C4医药公司 Targeted protein degradation
WO2022059996A1 (en) * 2020-09-15 2022-03-24 서울대학교 기술지주 주식회사 Blood circulation micro in-vitro corpuscle-mediated cancer treatment composition
KR102616469B1 (en) * 2020-09-15 2023-12-28 주식회사 유엔에스바이오 Composition for treatment of circulating small extracellular vesicles-mediated cancer
KR20230144529A (en) * 2020-12-16 2023-10-16 에이비엠 쎄라퓨틱스 코포레이션 Kinase inhibitors and uses thereof
CN119059982B (en) * 2024-07-18 2025-09-19 河北科技大学 Hydroxamic acid Mer/HDAC double-target inhibitor and preparation method and application thereof

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH549339A (en) * 1971-05-12 1974-05-31 Ciba Geigy Ag HERBICIDAL AGENT.
US5958930A (en) 1991-04-08 1999-09-28 Duquesne University Of The Holy Ghost Pyrrolo pyrimidine and furo pyrimidine derivatives
WO1997049706A1 (en) 1996-06-25 1997-12-31 Novartis Ag SUBSTITUTED 7-AMINO-PYRROLO[3,2-d]PYRIMIDINES AND THE USE THEREOF
US20080248046A1 (en) 1997-03-17 2008-10-09 Human Genome Sciences, Inc. Death domain containing receptor 5
GB9828511D0 (en) * 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
MXPA02010693A (en) * 2000-04-28 2003-03-10 Tanabe Seiyaku Co Cyclic compounds.
GB0016877D0 (en) * 2000-07-11 2000-08-30 Astrazeneca Ab Chemical compounds
WO2003029209A2 (en) 2001-10-02 2003-04-10 Smithkline Beecham Corporation Chemical compounds
JP4529685B2 (en) * 2002-06-28 2010-08-25 アステラス製薬株式会社 Diaminopyrimidine carboxamide derivatives
DE10239042A1 (en) 2002-08-21 2004-03-04 Schering Ag New fused macrocyclic pyrimidine derivatives, useful as e.g. cyclin-dependent kinase inhibitors for treating e.g. cancer, autoimmune, cardiovascular or neurodegenerative diseases or viral infections
EP1638966B1 (en) 2003-05-28 2008-03-19 Universita Degli Studi Di Siena 4-SUBSTITUTED DERIVATIVES OF PYRAZOLO ¬3,4-d PYRIMIDINE AND USES THEREOF
US7504396B2 (en) * 2003-06-24 2009-03-17 Amgen Inc. Substituted heterocyclic compounds and methods of use
EP2145888A1 (en) 2003-09-18 2010-01-20 Conforma Therapeutics Corporation Deazapurine derivatives as HSP90-Inhibitors
EP2260849A1 (en) 2004-01-21 2010-12-15 Emory University Compositions and methods of use for tyrosine kinase inhibitors to treat pathogenic infection
JP2007520559A (en) 2004-02-03 2007-07-26 アボット・ラボラトリーズ Aminobenzoxazoles as therapeutic agents
CN1918158B (en) 2004-02-14 2011-03-02 Irm责任有限公司 Compounds and compositions as protein kinase inhibitors
WO2005095382A1 (en) 2004-03-30 2005-10-13 Kyowa Hakko Kogyo Co., Ltd. Anti-tumor agent
US7897607B2 (en) 2004-04-07 2011-03-01 Takeda Pharmaceutical Company Limited Cyclic compounds
GB0420719D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
BRPI0516746A (en) * 2004-09-30 2008-09-23 Tibotec Pharm Ltd 5-heterocyclyl pyrimidines for hiv inhibition
US7906528B2 (en) 2004-10-05 2011-03-15 Novartis International Pharmaceutical Ltd. Pyrrolo-pyridine, pyrrolo-pyrimidine and related heterocyclic compounds
EP1710246A1 (en) 2005-04-08 2006-10-11 Schering Aktiengesellschaft Sulfoximine-pyrimidine Macrocycles and the salts thereof, a process for making them, and their pharmaceutical use against cancer
WO2007032445A1 (en) * 2005-09-16 2007-03-22 Kyowa Hakko Kogyo Co., Ltd. Protein kinase inhibitors
US20070105874A1 (en) 2005-09-23 2007-05-10 Conforma Therapeutics Corporation Anti-Tumor Methods Using Multi Drug Resistance Independent Synthetic HSP90 Inhibitors
CN101321751A (en) * 2005-09-30 2008-12-10 布里斯托尔-迈尔斯·斯奎布公司 Met kinase inhibitor
US7547782B2 (en) * 2005-09-30 2009-06-16 Bristol-Myers Squibb Company Met kinase inhibitors
WO2007044426A2 (en) 2005-10-06 2007-04-19 Schering Corporation Pyrazolopyrimidines as protein kinase inhibitors
DK1957539T3 (en) 2005-12-08 2013-05-06 Medarex Inc HUMAN MONOCLONAL ANTIBODIES FOR PROTEINTYROSINKINASE 7 (PTK7) AND THEIR USE
WO2007075554A2 (en) 2005-12-19 2007-07-05 Osi Pharmaceuticals, Inc. Combination of igfr inhibitor and anti-cancer agent
EP1803723A1 (en) 2006-01-03 2007-07-04 Bayer Schering Pharma Aktiengesellschaft (2,4,9-triaza-1(2,4)-pyrimidina-3(1,3)-benzenacyclononaphan-3^4-yl)-sulfoximide derivatives as selective inhibitors of the aurora kinase for the treatment of cancer
ES2465666T3 (en) * 2006-03-30 2014-06-06 Janssen R&D Ireland 5-amido-substituted pyrimidines HIV inhibitors
CA2651072A1 (en) 2006-05-01 2007-11-08 Pfizer Products Inc. Substituted 2-amino-fused heterocyclic compounds
GB0610242D0 (en) 2006-05-23 2006-07-05 Novartis Ag Organic compounds
JO3235B1 (en) 2006-05-26 2018-03-08 Astex Therapeutics Ltd Pyrroloperimidine compounds and their uses
US20100104567A1 (en) 2007-03-05 2010-04-29 Kyowa Hakko Kirin Co., Ltd. Pharmaceutical composition
WO2009032694A1 (en) 2007-08-28 2009-03-12 Dana Farber Cancer Institute Amino substituted pyrimidine, pyrollopyridine and pyrazolopyrimidine derivatives useful as kinase inhibitors and in treating proliferative disorders and diseases associated with angiogenesis
CA2702008A1 (en) 2007-10-12 2009-04-16 Ingenium Pharmaceuticals Gmbh Inhibitors of protein kinases
US8415361B2 (en) 2007-11-09 2013-04-09 The Salk Institute For Biological Studies Use of TAM receptor inhibitors as antimicrobials
US8338439B2 (en) * 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
SG10201510696RA (en) * 2008-06-27 2016-01-28 Celgene Avilomics Res Inc Heteroaryl compounds and uses thereof
US8399206B2 (en) 2008-07-10 2013-03-19 Nodality, Inc. Methods for diagnosis, prognosis and methods of treatment
US20120230991A1 (en) 2008-07-29 2012-09-13 Douglas Kim Graham Methods and compounds for enhancing anti-cancer therapy
US8569466B2 (en) 2008-09-10 2013-10-29 Nnochiri Ekwuribe Aromatic carboxylic acid derivatives for treatment and prophylaxis of gastrointestinal diseases including colon cancers
UY32158A (en) * 2008-10-03 2010-04-30 Astrazeneca Ab HETEROCICLIC DERIVATIVES AND METHODS OF USE OF THE SAME
GB0819105D0 (en) 2008-10-17 2008-11-26 Chroma Therapeutics Ltd Pyrrolo-pyrimidine compounds
US8513242B2 (en) 2008-12-12 2013-08-20 Cystic Fibrosis Foundation Therapeutics, Inc. Pyrimidine compounds and methods of making and using same
WO2010085597A1 (en) 2009-01-23 2010-07-29 Incyte Corporation Macrocyclic compounds and their use as kinase inhibitors
TW201102391A (en) 2009-03-31 2011-01-16 Biogen Idec Inc Certain substituted pyrimidines, pharmaceutical compositions thereof, and methods for their use
UA107791C2 (en) 2009-05-05 2015-02-25 Dow Agrosciences Llc Pesticidal compositions
AR076550A1 (en) * 2009-05-06 2011-06-22 Portola Pharm Inc INHIBITORS OF THE JANUS TIROSINA KINASA (JAK)
US8840889B2 (en) 2009-08-13 2014-09-23 The Johns Hopkins University Methods of modulating immune function
WO2011029915A1 (en) 2009-09-10 2011-03-17 Novartis Ag Ether derivatives of bicyclic heteroaryls
WO2011065800A2 (en) * 2009-11-30 2011-06-03 주식회사 오스코텍 Pyrimidine derivative, method for preparing same and pharmaceutical composition containing same
EP2536410B1 (en) 2010-02-18 2015-09-23 Merck Sharp & Dohme Corp. Substituted pyrimidine derivatives and their use in treating viral infections
GB201004311D0 (en) 2010-03-15 2010-04-28 Proximagen Ltd New enzyme inhibitor compounds
WO2011133920A1 (en) 2010-04-23 2011-10-27 Cytokinetics, Inc. Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use
US9290499B2 (en) 2010-05-19 2016-03-22 The University Of North Carolina At Chapel Hill Pyrazolopyrimidine compounds for the treatment of cancer
WO2011153553A2 (en) 2010-06-04 2011-12-08 The Regents Of The University Of California Methods and compositions for kinase inhibition
JP2014005206A (en) 2010-10-22 2014-01-16 Astellas Pharma Inc Arylamino heterocyclic carboxamide compound
RU2597609C2 (en) 2010-11-18 2016-09-10 Касина Лайла Иннова Фармасьютикалз Прайвит Лимитед Substituted 4-(selenophen-2(or 3)-ylamino) pyrimidine compounds and methods of use thereof
US8362023B2 (en) 2011-01-19 2013-01-29 Hoffmann-La Roche Inc. Pyrazolo pyrimidines
US8889684B2 (en) 2011-02-02 2014-11-18 Boehringer Ingelheim International Gmbh Azaindolylphenyl sulfonamides as serine/threonine kinase inhibitors
US9376438B2 (en) 2011-05-17 2016-06-28 Principia Biopharma, Inc. Pyrazolopyrimidine derivatives as tyrosine kinase inhibitors
CN103998442B (en) * 2011-08-29 2016-09-14 无限药品股份有限公司 Heterocyclic compound and application thereof
MD20140023A2 (en) 2011-09-22 2014-06-30 Pfizer Inc. Pyrrolopyrimidine and purine derivatives
WO2013052417A1 (en) 2011-10-03 2013-04-11 The University Of North Carolina At Chapel Hill Pyrrolopyrimidine compounds for the treatment of cancer
IN2014DN07022A (en) 2012-02-21 2015-04-10 Inst Nat Sante Rech Med
KR20160125527A (en) * 2012-04-17 2016-10-31 후지필름 가부시키가이샤 Nitrogen-containing heterocyclic compound or salt thereof
JP6182593B2 (en) 2012-04-20 2017-08-16 アドヴィーナス セラピューティクス リミテッド Substituted heterobicyclic compounds, compositions and medicaments and uses thereof
RU2014145121A (en) 2012-05-22 2016-07-10 Зэ Юниверсити Оф Норд Каролина Эт Чапел Хилл PYRIMIDINE COMPOUNDS FOR TREATING A MALIGNANT TUMOR
EP2909211A4 (en) 2012-10-17 2016-06-22 Univ North Carolina PYRAZOLOPYRIMIDINE COMPOUNDS FOR THE TREATMENT OF CANCER
EP2925752A4 (en) 2012-11-27 2016-06-01 Univ North Carolina PYRIMIDINE-BASED COMPOUNDS FOR USE IN THE TREATMENT OF CANCER
US20170202847A1 (en) 2014-04-04 2017-07-20 The University Of North Carolina At Chapel Hill Methods for the treatment of tumors
WO2015157122A1 (en) 2014-04-11 2015-10-15 The University Of North Carolina At Chapel Hill Mertk-specific pyrazolopyrimidine compounds

Also Published As

Publication number Publication date
CA2873878A1 (en) 2013-11-28
HK1206338A1 (en) 2016-01-08
EP2852579A1 (en) 2015-04-01
EP2852579A4 (en) 2015-12-30
CN104302627A (en) 2015-01-21
US9567326B2 (en) 2017-02-14
AU2013266438A1 (en) 2014-12-04
BR112014028424A2 (en) 2018-04-24
RU2014145121A (en) 2016-07-10
MX2014013632A (en) 2015-02-05
WO2013177168A1 (en) 2013-11-28
KR20150018789A (en) 2015-02-24
IL235726A0 (en) 2015-02-01
US20150038481A1 (en) 2015-02-05
AU2013266438B2 (en) 2017-09-07
JP2015517574A (en) 2015-06-22

Similar Documents

Publication Publication Date Title
IN2014DN09610A (en)
MX2016006432A (en) Tetrahydro-benzodiazepinones.
MX367897B (en) Macrocyclic pyridazinone derivatives.
PH12017500408A1 (en) Heteroaryl compunds as btk inhibitors and uses thereof
EP4458418A3 (en) Macrocyclic complexes of alpha-emitting radionuclides and their use in targeted radiotherapy of cancer
GEP20217330B (en) Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
MX2018005019A (en) Benzofuran derivative, preparation method thereof and use thereof in medicine.
EA030199B9 (en) Therapeutically active compounds and methods of use thereof
PH12015501576A1 (en) Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith
PH12016500225B1 (en) Novel quinoline-substituted compound
MX2015007097A (en) Novel bi-ring phenyl-pyridines/pyrazines for the treatment of cancer.
PH12016500643A1 (en) New octahydro - cyclobuta [1,2-c;3,4-c`] dipyrrol -2- yl
UA118666C2 (en) Novel pyrazol derivatives
MY186599A (en) Substituted pyridopyrazines as novel syk inhibitors
UA116239C2 (en) Novel pyridine derivatives
MX2014012477A (en) Pyrrolopyrazone inhibitors of tankyrase.
PH12016500347A1 (en) Triazolopyridine compounds, compositions and methods of use thereof
PH12015501175A1 (en) Substituted pyridopyrazines as syk inhibitors
PH12015501038A1 (en) Inhibitors of iap
MY170262A (en) Dicarboxylic acid compound
EP4585267A3 (en) Coumarin based hsp90 inhibitors with urea and ether substituents
MX2015016332A (en) Pyrrolotriazines as alk inhibitors.
UA112746C2 (en) Anti-Cancer Steroid Lactones Unsaturated in 7 (8)
PH12015500399A1 (en) Azaindolines
MX2016004509A (en) Nitrogen containing compounds and their use.